STOCK TITAN

[Form 4] Tourmaline Bio, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Tourmaline Bio (TRML) disclosed an insider ownership update. A company director reported a Code G transaction on 10/15/2025, indicating a distribution of 522 shares of common stock at $0.

Following the transaction, the reporting person directly holds 515,997 shares. An additional 431,939 shares are listed as indirectly held by KVP Capital, LP. Footnotes state this reflects an in-kind distribution by KVP to a limited partner for no consideration and a change in the form of ownership. The reporting person is associated with KVP’s general partner and disclaims beneficial ownership of KVP-held shares except for any pecuniary interest.

Tourmaline Bio (TRML) ha pubblicato un aggiornamento sull'azionariato interno. Un amministratore dell'azienda ha riportato una transazione di Codice G il 15/10/2025, indicando una distribuzione di 522 azioni ordinarie a $0.

Dopo la transazione, la persona che ha presentato il rapporto detiene direttamente 515.997 azioni. Altre 431.939 azioni sono elencate come detenute indirettamente da KVP Capital, LP. Le note a piè di pagina indicano che ciò riflette una distribuzione in natura da parte di KVP a un socio comanditario senza contrapprestazione e un cambiamento nella forma di proprietà. La persona che ha presentato il rapporto è associata al socio generale di KVP e declina la proprietà beneficiaria delle azioni detenute da KVP salvo qualsiasi interesse pecuniario.

Tourmaline Bio (TRML) divulgó una actualización sobre la propiedad de insiders. Un director de la empresa reportó una operación de Código G el 15/10/2025, indicando una distribución de 522 acciones de capital social común a $0.

Tras la operación, la persona que reporta posee directamente 515,997 acciones. Otras 431,939 acciones figuran como poseídas indirectamente por KVP Capital, LP. Las notas al pie señalan que esto refleja una distribución en especie por parte de KVP a un socio limitado sin contrapartida y un cambio en la forma de propiedad. La persona que reporta está asociada con el socio general de KVP y renuncia a la propiedad beneficiosa de las acciones poseídas por KVP, excepto por cualquier interés pecuniario.

투몰레인 바이오 (Tourmaline Bio, TRML)는 내부자 보유 현황 업데이트를 공개했습니다. 회사 이사는 2025년 10월 15일에 Code G 거래를 보고했고, 보통주 522주$0에 배당한다고 밝혔습니다.

거래 후 보고자는 직접 보유한 주식이 515,997주이며, 추가로 431,939주가 간접 보유로 KVP Capital, LP에 기재되어 있습니다. 각주에 따르면 이는 KVP가 무대가치로 한 파트너에게 비현물 분배를 한 것과 소유 형태의 변경을 반영합니다. 보고자는 KVP의 일반 파트너와 연계되어 있으며, KVP가 보유한 주식에 대한 실질적 소유권을 배제하고, 재정적 이해가 있는 경우를 제외하고는 포기한다고 밝힙니다.

Tourmaline Bio (TRML) a publié une mise à jour sur la possession d’initiés. Un administrateur de la société a signalé une transaction Code G le 15/10/2025, indiquant une distribution de 522 actions ordinaires à $0.

Après la transaction, la personne qui dépose le rapport détient directement 515 997 actions. À titre indirect, 431 939 actions sont détenues par KVP Capital, LP. Les notes de bas de page indiquent que cela reflète une distribution en nature par KVP à un partenaire limité sans contrepartie et un changement dans la forme de propriété. La personne déposant le rapport est associée au partenaire général de KVP et décline toute propriété bénéficiaire des actions détenues par KVP, sauf pour tout intérêt pécuniaire.

Tourmaline Bio (TRML) hat ein Update zum Insiderbesitz veröffentlicht. Ein Unternehmensdirektor meldete am 15.10.2025 eine Transaktion nach Code G, die eine Ausschüttung von 522 Aktien Stammaktien zu $0 anzeigt.

Nach der Transaktion hält die meldende Person direkt 515.997 Aktien. Zusätzlich sind 431.939 Aktien als indirekt von KVP Capital, LP gehalten aufgeführt. Fußnoten besagen, dass dies eine in-kind Verteilung durch KVP an einen Limited Partner ohne Gegenleistung und eine Veränderung der Eigentumsform widerspiegelt. Die meldende Person ist mit dem General Partner von KVP verbunden und bestreitet einen wirtschaftlichen Eigentumsanteil an den von KVP gehaltenen Aktien, außer etwaige finanzielle Interessen.

Tourmaline Bio (TRML) أعلنت عن تحديث بخصوص الملكية الداخلية. أبلغ أحد مديري الشركة عن صفقة من نوع Code G في 15/10/2025، تشير إلى توزيع 522 سهماً من الأسهم العادية بسعر $0.

بعد الصفقة، يمتلك الشخص المُبلغ عنها مباشرة 515,997 سهماً. كما أن 431,939 سهماً أخرى مذكورة كملكية غير مباشرة لصالح KVP Capital, LP. تشير الحواشي إلى أن ذلك يعكس توزيعاً عينيّاً من قبل KVP لشريك محدود بدون مقابل وتغييراً في شكل الملكية. الشخص المُبلغ مرتبط بشريك التشغيل العام لـ KVP وينفي الملكية المفيدة للأسهم المملوكة من KVP باستثناء أي مصلحة مالية.

Tourmaline Bio (TRML) 披露了内幕持股更新。公司董事在 2025/10/15 报告了 Code G 交易,表明以 $0 价格分配 522 股普通股

交易后,申报人直接持有 515,997 股;另外还有 431,939 股被列为由 KVP Capital, LP 间接持有。脚注显示这反映了 KVP 无对价向有限合伙人进行的实物分配以及所有权形式的变更。申报人与 KVP 的普通合伙人有关联,除任何金钱利益外,否认对 KVP 持有的股票享有实益所有权。

Positive
  • None.
Negative
  • None.

Tourmaline Bio (TRML) ha pubblicato un aggiornamento sull'azionariato interno. Un amministratore dell'azienda ha riportato una transazione di Codice G il 15/10/2025, indicando una distribuzione di 522 azioni ordinarie a $0.

Dopo la transazione, la persona che ha presentato il rapporto detiene direttamente 515.997 azioni. Altre 431.939 azioni sono elencate come detenute indirettamente da KVP Capital, LP. Le note a piè di pagina indicano che ciò riflette una distribuzione in natura da parte di KVP a un socio comanditario senza contrapprestazione e un cambiamento nella forma di proprietà. La persona che ha presentato il rapporto è associata al socio generale di KVP e declina la proprietà beneficiaria delle azioni detenute da KVP salvo qualsiasi interesse pecuniario.

Tourmaline Bio (TRML) divulgó una actualización sobre la propiedad de insiders. Un director de la empresa reportó una operación de Código G el 15/10/2025, indicando una distribución de 522 acciones de capital social común a $0.

Tras la operación, la persona que reporta posee directamente 515,997 acciones. Otras 431,939 acciones figuran como poseídas indirectamente por KVP Capital, LP. Las notas al pie señalan que esto refleja una distribución en especie por parte de KVP a un socio limitado sin contrapartida y un cambio en la forma de propiedad. La persona que reporta está asociada con el socio general de KVP y renuncia a la propiedad beneficiosa de las acciones poseídas por KVP, excepto por cualquier interés pecuniario.

투몰레인 바이오 (Tourmaline Bio, TRML)는 내부자 보유 현황 업데이트를 공개했습니다. 회사 이사는 2025년 10월 15일에 Code G 거래를 보고했고, 보통주 522주$0에 배당한다고 밝혔습니다.

거래 후 보고자는 직접 보유한 주식이 515,997주이며, 추가로 431,939주가 간접 보유로 KVP Capital, LP에 기재되어 있습니다. 각주에 따르면 이는 KVP가 무대가치로 한 파트너에게 비현물 분배를 한 것과 소유 형태의 변경을 반영합니다. 보고자는 KVP의 일반 파트너와 연계되어 있으며, KVP가 보유한 주식에 대한 실질적 소유권을 배제하고, 재정적 이해가 있는 경우를 제외하고는 포기한다고 밝힙니다.

Tourmaline Bio (TRML) a publié une mise à jour sur la possession d’initiés. Un administrateur de la société a signalé une transaction Code G le 15/10/2025, indiquant une distribution de 522 actions ordinaires à $0.

Après la transaction, la personne qui dépose le rapport détient directement 515 997 actions. À titre indirect, 431 939 actions sont détenues par KVP Capital, LP. Les notes de bas de page indiquent que cela reflète une distribution en nature par KVP à un partenaire limité sans contrepartie et un changement dans la forme de propriété. La personne déposant le rapport est associée au partenaire général de KVP et décline toute propriété bénéficiaire des actions détenues par KVP, sauf pour tout intérêt pécuniaire.

Tourmaline Bio (TRML) hat ein Update zum Insiderbesitz veröffentlicht. Ein Unternehmensdirektor meldete am 15.10.2025 eine Transaktion nach Code G, die eine Ausschüttung von 522 Aktien Stammaktien zu $0 anzeigt.

Nach der Transaktion hält die meldende Person direkt 515.997 Aktien. Zusätzlich sind 431.939 Aktien als indirekt von KVP Capital, LP gehalten aufgeführt. Fußnoten besagen, dass dies eine in-kind Verteilung durch KVP an einen Limited Partner ohne Gegenleistung und eine Veränderung der Eigentumsform widerspiegelt. Die meldende Person ist mit dem General Partner von KVP verbunden und bestreitet einen wirtschaftlichen Eigentumsanteil an den von KVP gehaltenen Aktien, außer etwaige finanzielle Interessen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Castelein Caley

(Last) (First) (Middle)
C/O TOURMALINE BIO, INC.
27 WEST 24TH STREET, SUITE 702

(Street)
NEW YORK NY 10010

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Tourmaline Bio, Inc. [ TRML ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/15/2025 G 522 D $0 515,997 D
Common Stock 431,939(1) I By KVP Capital, LP(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Gives effect to in-kind distribution of shares by KVP Capital, LP ("KVP") to its limited partner for no consideration, subsequent to the Reporting Person's most recent filing, which represented a change in the form of the Reporting Person's ownership that was not required to be reported under Section 16.
2. These shares are held by KVP. The Reporting Person is the Managing Member of KVP Capital GP, LLC, the General Partner of KVP and, as such, has sole voting and investment power with respect to the shares held by KVP. The Reporting Person disclaims beneficial ownership of the shares held by KVP except to the extent of his pecuniary interest therein and this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
/s/ Brad Middlekauff, Attorney-in-Fact 10/17/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the TRML insider report on Form 4?

A director reported a Code G distribution of 522 shares on 10/15/2025 at $0.

How many TRML shares does the reporting person hold directly after the transaction?

Direct holdings are 515,997 shares following the reported transaction.

Are there indirect TRML holdings reported?

Yes. 431,939 shares are indirectly held by KVP Capital, LP, per the filing.

What does Transaction Code G mean here?

The filing notes an in-kind distribution for no consideration, consistent with a Code G transfer.

Does the reporting person claim beneficial ownership of KVP-held shares?

The reporting person disclaims beneficial ownership of KVP-held shares except to the extent of any pecuniary interest.

What explains the change in ownership form?

Footnotes state KVP distributed shares in-kind to a limited partner, reflecting a change in ownership form.
Tourmaline Bio

NASDAQ:TRML

TRML Rankings

TRML Latest News

TRML Latest SEC Filings

TRML Stock Data

1.23B
21.73M
22.06%
89.92%
10.33%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
NEW YORK